Cernostics Announces Blinded, Independent Validation of TissueCypher ® Performance for Predicting Risk of Progression to Esophageal Cancer in Patients with Non-Dysplastic BE

Study further validates TissueCypher® as the first and only precision medicine test proven to provide actionable data for predicting patient progression to high-grade dysplasia and esophageal adenocarcinoma Pittsburgh, Penn., June 25, 2020 – Cerno... Read more
Customer Service

Mon-Fri 9am-5pm (EST)